http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Knight and TherapeuticsMD (TXMD) Announce Health Canada Approval of IMVEXXY
-
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
-
TherapeuticsMD® Announces Second Quarter 2020 Financial Results
-
TherapeuticsMD to Report Second Quarter 2020 Results on August 6, 2020
-
TherapeuticsMD (TXMD) and Nurx Expand Access to ANNOVERA
-
TherapeuticsMD and Nurx Expand Access to ANNOVERA®
-
TherapeuticsMD (TXMD) Announces James C. D’Arecca as New CFO, Following Retirement of CFO Daniel A. Cartwright
-
TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer
-
TherapeuticsMD Announces Participation at the BofA Securities 2020 Health Care Conference
-
TherapeuticsMD (TXMD) Announces Issuance of First Orange Book Listable U.S. Patent for ANNOVERA
-
TherapeuticsMD Announces Issuance of First Orange Book Listable U.S. Patent for ANNOVERA®
-
TherapeuticsMD to Report First Quarter 2020 Results on May 6, 2020
-
TherapeuticsMD (TXMD) Appoints Tommy G. Thompson to Board
-
TherapeuticsMD Further Strengthens Board with Appointment of New Independent Director
-
TherapeuticsMD (TXMD) is Suspending 2020 Financial Guidance
-
TherapeuticsMD Provides COVID-19-Related Business Update
-
TherapeuticsMD (TXMD) Announces Paul Bisaro and Gail Naughton, Ph.D. to Board
-
TherapeuticsMD Strengthens Board with Appointment of Industry Leaders
-
TherapeuticsMD (TXMD) Announces Business Update on COVID-19 Pandemic
-
TherapeuticsMD Provides Business Update on COVID-19 Pandemic
-
TherapeuticsMD Announces Participation at the Cowen 40th Annual Healthcare Conference
-
TherapeuticsMD and Afaxys Enter Into Agreement to Expand Access to ANNOVERA® in the U.S. Public Health Sector
-
TherapeuticsMD to Report Fourth Quarter 2019 Results on February 20, 2020
-
TherapeuticsMD (TXMD) Announces NDA Prior Approval Efficacy Supplement to FDA for Lower Dose of BIJUVA
-
TherapeuticsMD Announces Submission of New Drug Application Prior Approval Efficacy Supplement to the U.S. Food and Drug Administration for Lower Dose of BIJUVA®
-
TherapeuticsMD, an Innovative Women’s Healthcare Company, and PlushCare, a Virtual Health Platform, Announce Enhanced Access to Women’s Health Products
-
TherapeuticsMD, An Innovative Women's Healthcare Company, And PlushCare, A Virtual Health Platform, Announce Enhanced Access To Women's Health Products
-
TherapeuticsMD Announces Participation at the JP Morgan Healthcare Conference
-
TherapeuticsMD Announces Amendment to Term Loan Financing Facility with TPG Sixth Street Partners
-
Knight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA® in Canada
-
TherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference
-
TherapeuticsMD Announces Third Quarter 2019 Financial Results
-
TherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019
-
Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada
-
Pre-Open 10/24: (TSLA) (AYR) (PYPL) Higher (ACOR) (TWTR) (TXMD) Lower (more...)
-
TherapeuticsMD Announces Presentations on ANNOVERA™ at the 2019 Annual Meeting of the American Society for Reproductive Medicine
-
TherapeuticsMD Vice President of Business Development Named Finalist in 16th Annual Stevie® Awards for Women in Business
-
TherapeuticsMD Announces Participation at the 2019 Cantor Healthcare Conference
-
TherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society
-
TherapeuticsMD Announces Second Quarter 2019 Financial Results
-
TherapeuticsMD to Report Second Quarter 2019 Results on August 6, 2019
-
TherapeuticsMD to Host Investor and Analyst Day Today
-
TherapeuticsMD (TXMD) Reports Exclusive License and Supply Agreement with Theramex to Commercialize BIJUVA & IMVEXXY Outside the U.S.
-
TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
-
TherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City
-
TherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference
-
TherapeuticsMD Announces First Quarter 2019 Financial Results
-
TherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men
-
TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting
-
TherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019

